Comparison of the Therapeutic Effect of Erythropoietin Alone and with the Combination of L-Carnitine on Hemoglobin Levels in Hemodialysis Patients
,
Abstract
Background: L-carnitine deficiency causes various pathological conditions such as muscle weakness and erythropoietin-resistant anemia in hemodialysis patients. The present study was conducted to compare the therapeutic effect of erythropoietin alone and with the combination of L-carnitine on anemia in hemodialysis patients
Method: In this clinical trial, 24 patients undergoing hemodialysis at Imam Ali Hospital were selected for the study. The eligible participants were randomly assigned into two equal groups: one group received erythropoietin treatment alone, while the other group was treated with a combination of L-carnitine and erythropoietin. Blood samples were collected from all patients for a complete blood count (CBC), and their hemoglobin levels were measured both before and after the treatment.
Results: The mean age of patients in the erythropoietin-only treatment group was 18.66±3.70 years, while in the group receiving both erythropoietin and L-carnitine, it was 23.83±5.70 years. A significant difference in age was found between the two groups (P=0.015). However, there was no significant difference in hemoglobin levels between the groups before treatment (P=0.327). After treatment, the mean hemoglobin levels in the erythropoietin group and the combination therapy group were 9.8±1.6 and 10.6±3.9 g/dL, respectively, with no significant difference observed between the two groups in terms of hemoglobin (P=0.324).
Conclusion: Our findings indicated that treatment with erythropoietin alone, as well as in combination with L-carnitine, did not lead to a significant improvement in blood parameters in hemodialysis patients with anemia.
2. Kaur G, Hussain MS, Mohit KTKataria T. A review of acute or chronic renal failure, common kidney diseases, and herbal plants used for management. Int J Bot Stud. 2021;6:50-56.
3. Zelmer J. The economic burden of end-stage renal disease in Canada. Kidney international. 2007;72(9):1122-29.
4. Silverberg D, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, et al. The effect of iv iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clinical nephrology. 2001;55(3):212-19.
5. Hasegawa T, Koiwa FAkizawa T, editors. Anemia in conventional hemodialysis: finding the optimal treatment balance. Seminars in dialysis; 2018: Wiley Online Library.
6. Jungers PY, Robino C, Choukroun G, Nguyen‐Khoa T, Massy ZAJungers P. Incidence of anaemia, and use of epoetin therapy in pre‐dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant. 2002;17(9):1621-27.
7. Kathleen DJames T. Mosby’s diagnostic and laboratory test reference. Mosby year book. 1992:843.
8. Jalalzadeh M, Shekari E, Mirzamohammadi FGhadiani M. Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients. Indian J Nephrol. 2012;22(3):168-73.
9. Chen W-T, Lin Y-F, Yu F-C, Kao W-Y, Huang W-HYan H-C. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Am J Kidney Dis. 2003;42(1):158-66.
10. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38(4):955-62.
11. Harpaz S. L-carnitine and its attributed functions in fish culture and nutrition—a review. Aquaculture. 2005;249(1-4):3-21.
12. Ramezanpour M, Matboo MHejazi EM. The effect of four weeks aerobic training with using L-carnitine supplement on lipid profile and blood glucose in diabetic men. Med J Mashhad Univ Med Sci. 2015;58(6):316-21.
13. Emami Naini A, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, et al. Effects of oral L‐carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: A randomized, double‐blinded, placebo‐controlled trial. J Nutr Metab. 2012;2012(1):510483.
14. Takashima H, Maruyama TAbe M. Significance of levocarnitine treatment in dialysis patients. Nutrients. 2021;13(4):1219.
15. Baghban F, Hosseinzadeh M, Mozaffari-Khosravi H, Dehghan AFallahzadeh H. The effect of L-carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial. BMC Musculoskeletal Disorders. 2021;22:1-9.
16. SADEGHI S, Firouzan A, MAZIYAR S, Mahdavi MNikrouy N. Refractory anemia after epoetin therapy in patients with chronic renal failure. 2006.
17. Asl BH, Khosrovshahy HTGhanbarzadeh S. Comparison of the effect of erythropoietin and erythropoietin with oral solution of carnitine in treatment of anemia in hemodialysis patients. Res Pharm Sci. 2012;7(5):921.
18. Verrina E, Caruso U, Calevo MG, Emma F, Sorino P, De Palo T, et al. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol. 2007;22:727-33.
19. Higuchi T. Effects of levocarnitine on cardiac function and renal anemia in hemodialysis patients. Recent Advances in Dialysis Therapy in Japan. 2018;196:96-100.
| Files | ||
| Issue | Vol 6, No 4 (2023) | |
| Section | Original Article | |
| DOI | https://doi.org/10.18502/igj.v6i4.17098 | |
| Keywords | ||
| Erythropoietin Hemoglobin Hemodialysis L-Carnitine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
